TABLE 2.
Treatments | Second instar | Fourth instar | ||||||
Observed mortality (%) | Expected mortality | CTF | Type of interaction | Observed mortality (%) | Expected mortality | CTF | Type of interaction | |
Bb | 27.13 ± 1.36d | 19.69 ± 1.19e | ||||||
Bt1 | 19.96 ± 1.11d | 14.87 ± 1.07e | ||||||
Bt2 | 33.64 ± 2.02d | 25.74 ± 1.25de | ||||||
Bt3 | 58.05 ± 2.80bc | 49.36 ± 2.34bc | ||||||
Bb + Bt1 | 49.07 ± 2.13c | 47.09 | 4.03 | Additive | 35.92 ± 1.70cd | 34.56 | 3.78 | Additive |
Bb + Bt2 | 77.40 ± 3.10a | 60.77 | 21.48 | Synergistic | 58.82 ± 2.77a | 45.43 | 22.76 | Synergistic |
Bb + Bt3 | 68.38 ± 3.03ab | 85.18 | −24.5 | Antagonistic | 53.45 ± 2.31ab | 65.05 | −21.70 | Antagonistic |
df | 6 | - | - | 6 | - | - | ||
F | 40.6 | - | - | 31.6 | - | - | ||
P | ≤ 0.05 | - | - | ≤0.05 | - | - |
Means followed by the same letters within each column are not significantly different; HSD test P ≤ 0.05.